Vanguard Group Inc. Increases Holdings in Insmed Incorporated (NASDAQ:INSM)

Vanguard Group Inc. boosted its position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 6.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 18,218,973 shares of the biopharmaceutical company's stock after purchasing an additional 1,075,796 shares during the period. Vanguard Group Inc. owned about 10.18% of Insmed worth $1,257,838,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vestal Point Capital LP grew its stake in shares of Insmed by 113.3% during the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company's stock valued at $116,800,000 after buying an additional 850,000 shares during the last quarter. Eventide Asset Management LLC grew its position in Insmed by 34.2% in the 3rd quarter. Eventide Asset Management LLC now owns 906,395 shares of the biopharmaceutical company's stock valued at $66,167,000 after acquiring an additional 231,210 shares during the last quarter. Principal Financial Group Inc. increased its stake in Insmed by 12.9% in the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company's stock worth $136,648,000 after purchasing an additional 214,130 shares during the period. TimesSquare Capital Management LLC increased its stake in Insmed by 41.4% in the fourth quarter. TimesSquare Capital Management LLC now owns 684,384 shares of the biopharmaceutical company's stock worth $47,250,000 after purchasing an additional 200,515 shares during the period. Finally, abrdn plc lifted its position in shares of Insmed by 159.5% during the fourth quarter. abrdn plc now owns 289,653 shares of the biopharmaceutical company's stock worth $19,998,000 after purchasing an additional 178,041 shares during the last quarter.

Remove Ads

Insmed Stock Down 5.6 %

INSM traded down $4.29 on Tuesday, hitting $72.00. The company had a trading volume of 2,723,547 shares, compared to its average volume of 2,234,377. The stock has a market capitalization of $13.03 billion, a price-to-earnings ratio of -12.88 and a beta of 1.28. The stock has a fifty day moving average price of $78.16 and a 200-day moving average price of $74.00. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The firm had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Analysts predict that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insider Transactions at Insmed

In other news, CEO William Lewis sold 18,750 shares of the company's stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $69.84, for a total transaction of $1,309,500.00. Following the transaction, the chief executive officer now owns 384,960 shares in the company, valued at $26,885,606.40. This represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Sara Bonstein sold 3,470 shares of the stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $65.70, for a total transaction of $227,979.00. Following the completion of the transaction, the chief financial officer now directly owns 114,736 shares of the company's stock, valued at $7,538,155.20. The trade was a 2.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 550,957 shares of company stock valued at $42,992,528. Corporate insiders own 4.60% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on INSM shares. Morgan Stanley raised their price target on shares of Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. Stifel Nicolaus reduced their target price on shares of Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a research report on Friday, February 21st. Wells Fargo & Company boosted their price target on Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a report on Wednesday, February 19th. JPMorgan Chase & Co. raised their price objective on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a report on Friday, February 7th. Finally, Bank of America lifted their target price on Insmed from $92.00 to $96.00 and gave the company a "buy" rating in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $94.00.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.